Condition: HIV Infections · Sponsor: ViiV Healthcare
The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA \[Ribonucleic Acid\] \< 50 \[cells per milliliter\] c/mL) children 6 to less than 12 years of age, weighing at least 25 kilogram (kg).
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Long Beach, California, United States | Recruiting |
| GSK Investigational Site | Washington D.C., District of Columbia, United States | Recruiting |
| GSK Investigational Site | Fort Lauderdale, Florida, United States | Completed |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
| GSK Investigational Site | Tampa, Florida, United States | Recruiting |
| GSK Investigational Site | Atlanta, Georgia, United States | Recruiting |
| GSK Investigational Site | Houston, Texas, United States | Recruiting |
| GSK Investigational Site | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05674656